18F-氟雌二醇PET/CT在浸润性小叶癌患者中的前瞻性初步研究
这项前瞻性单中心初步研究纳入17例组织学确诊的浸润性小叶癌患者,评估氟雌二醇(FES)PET/CT对已知病灶的异常摄取显示率。
要点
- FES PET/CT对组织学确诊的浸润性小叶癌病灶异常摄取率高(88%),可作为ER表达评估手段。
- FES PET/CT可检出标准评估遗漏的额外病灶(对侧乳腺癌、转移性腋窝淋巴结),影响分期。
- FES与FDG PET/CT互补,部分病灶仅一种示踪剂阳性,联合应用可能更全面。
关键影像表现/征象
- FES PET/CT在25个已知浸润性小叶癌病灶中显示22个(88%)异常摄取。
- FES PET/CT在4/17(24%)患者中检出标准评估未发现的额外病灶(2个对侧乳腺癌、2个转移性腋窝淋巴结),均经组织学证实。
诊断标准与关键数值
- FES PET/CT导致3/17(18%)患者临床分期相对于标准评估发生改变。
临床应用与阅片要点
- 对浸润性小叶癌患者,FES PET/CT可辅助评估ER表达状态及全身病灶分布。
- FES PET/CT可检出标准影像评估遗漏的对侧乳腺癌或转移性淋巴结,阅片时应仔细排查。
- FES与FDG PET/CT所见不完全一致,必要时可考虑联合应用以全面评估病灶。
局限性
- 单中心前瞻性初步研究,样本量小(17例患者,25个病灶),结果需更大规模研究验证。
- 部分患者未行FDG PET/CT,两种示踪剂对比的样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. PET/CT with 18F-fluoroestradiol (FES) (FDA-approved in 2020) depicts tissues expressing estrogen receptor (ER). Invasive lobular carcinoma (ILC) is commonly ER positive. OBJECTIVE. The primary aim of this study was to assess the frequency with which sites of histologically proven ILC have abnormal uptake on FES PET/CT. METHODS. This prospective single-center pilot study, conducted from December 2020 to August 2021, enrolled patients with histologically confirmed ILC to undergo FES PET/CT; patients optionally underwent FDG PET/CT. Two nuclear radiologists assessed FES PET/CT and FDG PET/CT studies for abnormal uptake corresponding to known ILC sites at enrollment and for additional sites of abnormal uptake, resolving differences by consensus. The primary endpoint was percentage of known ILC sites showing abnormal FES uptake. The alternative to the null hypothesis was that more than 60% of sites would have abnormal FES uptake, exceeding the percentage of ILC with abnormal FDG uptake described in prior literature. A sample size of 24 biopsied lesions was preselected to provide 81% power for the alternative hypothesis (one-sided α = .10). Findings on FES PET/CT and FDG PET/CT were summarized for additional secondary endpoints. RESULTS. The final analysis included 17 patients (mean age, 59.1 ± 13.2 years) with 25 sites of histologically confirmed ILC at enrollment (22 breast lesions, two axillary lymph nodes, one distant metastasis). FES PET/CT showed abnormal uptake in 22 of 25 (88%) lesions, sufficient to reject the null hypothesis (p = .002). Thirteen patients underwent FDG PET/CT. Four of 23 (17%) sites of histologically confirmed ILC, including additional sites detected and confirmed after enrollment, were identified with FES PET/CT only, and 1 of 23 (4%) was identified only with FDG PET/CT (p = .18). FES PET/CT depicted additional lesions not detected with standard-of-care evaluation in 4 of 17 (24%) patients (two contralateral breast cancers and two metastatic axillary lymph nodes, all with subsequent histologic confirmation). Use of FES PET/CT resulted in changes in clinical stage with respect to standard-of-care evaluation in 3 of 17 (18%) patients. CONCLUSION. The primary endpoint of the trial was met. The frequency of abnormal FES uptake among sites of histologically known ILC was found to be to be significantly greater than 60%. CLINICAL IMPACT. This pilot study shows a potential role of FES PET/CT in evaluation of patients with ILC. TRIAL REGISTRATION. ClinicalTrials.gov NCT04252859.
引用
- Covington, Hoffman, Morton, et al. Prospective Pilot Study of 18F-Fluoroestradiol PET/CT in Patients With Invasive Lobular Carcinomas. AJR Am J Roentgenol. 2023. PMID: 36919879. doi:10.2214/AJR.22.28809
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。